Literature DB >> 9712844

N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities.

P Loetscher1, J H Gong, B Dewald, M Baggiolini, I Clark-Lewis.   

Abstract

Peptides corresponding to the N-terminal 9 residues of stromal cell-derived factor-1 (SDF-1) have SDF-1 activity. SDF-1, 1-8, 1-9, 1-9 dimer, and 1-17 induced intracellular calcium and chemotaxis in T lymphocytes and CEM cells and bound to CXC chemokine receptor 4 (CXCR4). The peptides had similar activities to SDF-1 but were less potent. Whereas native SDF-1 had half-maximal chemoattractant activity at 5 nM, the 1-9 dimer required 500 nM and was therefore 100-fold less potent. The 1-17 and a 1-9 monomer analog were 4- and 36-fold, respectively, less potent than the 1-9 dimer. Both the chemotactic and calcium response of the 1-9 dimer was inhibited by an antibody to CXCR4. The basis for the enhanced activity of the dimer form of SDF-1, 1-9 is uncertain, but it could involve an additional fortuitous binding site on the 1-9 peptide in addition to the normal SDF-1, 1-9 site. A 1-9 analog, 1-9[P2G] dimer, was found to be a CXCR4 antagonist. Overall this study shows that the N-terminal peptides are CXCR4 agonists or antagonists, and these could be leads for high affinity ligands.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712844     DOI: 10.1074/jbc.273.35.22279

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Characterization of Nef-CXCR4 interactions important for apoptosis induction.

Authors:  Ming-Bo Huang; Ling Ling Jin; Cleve O James; Mahfuz Khan; Michael D Powell; Vincent C Bond
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 2.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

Review 3.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 4.  Structural basis of chemokine receptor function--a model for binding affinity and ligand selectivity.

Authors:  Lavanya Rajagopalan; Krishna Rajarathnam
Journal:  Biosci Rep       Date:  2006-10       Impact factor: 3.840

5.  The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1α function through distinct receptor interactions.

Authors:  Vikas Saini; Daniel M Staren; Joshua J Ziarek; Zayd N Nashaat; Edward M Campbell; Brian F Volkman; Adriano Marchese; Matthias Majetschak
Journal:  J Biol Chem       Date:  2011-07-13       Impact factor: 5.157

6.  Effects of exogenous ubiquitin in a polytrauma model with blunt chest trauma.

Authors:  Todd A Baker; Jacqueline Romero; Harold H Bach; Joel A Strom; Richard L Gamelli; Matthias Majetschak
Journal:  Crit Care Med       Date:  2012-08       Impact factor: 7.598

Review 7.  Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases.

Authors:  Won-Tak Choi; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2011-05-12

8.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

9.  Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.

Authors:  Martyna Szpakowska; Amanda M Nevins; Max Meyrath; David Rhainds; Thomas D'huys; François Guité-Vinet; Nadine Dupuis; Pierre-Arnaud Gauthier; Manuel Counson; Andrew Kleist; Geneviève St-Onge; Julien Hanson; Dominique Schols; Brian F Volkman; Nikolaus Heveker; Andy Chevigné
Journal:  Br J Pharmacol       Date:  2018-03-23       Impact factor: 8.739

10.  On-column refolding of recombinant chemokines for NMR studies and biological assays.

Authors:  Christopher T Veldkamp; Francis C Peterson; Paulette L Hayes; Jessie E Mattmiller; John C Haugner; Norberto de la Cruz; Brian F Volkman
Journal:  Protein Expr Purif       Date:  2006-09-24       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.